South Orange, New Jersey--(Newsfile Corp. - February 28, 2022) - Nephros, Inc. (NASDAQ: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced that Andy Astor, Chief Executive Officer of Nephros will be attending the Q1 Virtual Investor Summit. During the Presentation, Mr. Astor will provide an overview of the business and its growth prospects.
Event: Q1 Investor Summit
Date: March 8-9th, 2022
Presentation: March 8th at 9:30am ET
Location: https://us06web.zoom.us/webinar/register/WN_DOdiU-ZFT8yZzlJEn_9o_w
- 1x1s will be available for qualified investors
- The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration
About the Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com
About Nephros
Nephros, Inc. is a company committed to improving the human relationship with water through leading, accessible technology. We provide innovative filtration and pathogen detection as part of an integrated approach to water safety that combines science, solutions, and support services. Nephros products serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency responses for water management. For more information about Nephros, please visit www.nephros.com.
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Andy Astor, CEO
Nephros, Inc.
(201) 345-0824
andy.astor@nephros.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114928